A Phase II Study of Busulfan & Melphalan as Conditioning Regimen for ASCT in Patients Who Received Bortezomib Based Induction for Newly Diagnosed Multiple Myeloma Followed by Lenalidomide Maintenance Until Progression.
A number of strategies have been proposed to improve the outcome of ASCT. The three main
strategies are to incorporate novel agents into the induction regimen, using maintenance
therapy following ASCT and the final strategy is to enhance conditioning regimens.
Investigators would like to explore all these three strategies in this study: Investigators
propose to take patients who have had standard novel agent (bortezomib) based induction
regimens into this study and then use a dose-adjusted combination of busulfan and melphalan
as conditioning regimen and finally Investigators would like to incorporate lenalidomide
maintenance post ASCT until disease progression.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society